From Fred Alger Management: Cabaletta是一家临床阶段的生物技术公司,专注于发现和开发自身免疫性疾病的靶向细胞疗法。
该公司的主要候选药物 CABA-201 是一种治疗狼疮和肌炎的细胞疗法,美国食品和药物管理局已接受 CABA-201 的新药申请,为 1/2 期的初步读数...查看全文
产业链观察2022-10-11 19:19
药闻▶2022年10月11日,中国南京和上海,美国宾夕法尼亚州费城和加利福尼亚州圣何塞,——驯鹿生物(“IASO Bio”),一家处于临床阶段、致力于细胞创新药物开发的生物制药公司与$Cabaletta Bio(CABA)$ ,一家致力于针对自身免疫性疾病患者开发和商业化的首个靶向细胞疗法的临床阶段...查看全文
$Cabaletta Bio(CABA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000929638-24-000640 Act: 34 Size: 123 KB 网页链接
$Cabaletta Bio(CABA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902664-24-001609 Act: 34 Size: 67 KB 网页链接
$Cabaletta Bio(CABA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-24-034084 Act: 34 Size: 49 KB 网页链接
$Cabaletta Bio(CABA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-24-033809 Act: 34 Size: 47 KB 网页链接
$Cabaletta Bio(CABA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193805-24-000180 Act: 34 Size: 130 KB 网页链接
$Cabaletta Bio(CABA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902664-24-001128 Act: 34 Size: 98 KB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001193125-24-021894 Act: 34 Size: 191 KB 网页链接
$Cabaletta Bio(CABA)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0000093751-24-000134 Act: 34 Size: 8 KB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-005888 Size: 10 KB 网页链接
$Cabaletta Bio(CABA)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001086364-24-000182 Act: 34 Size: 13 KB 网页链接